Merck & Co. Statistics
Total Valuation
Merck & Co. has a market cap or net worth of $317.16 billion. The enterprise value is $345.12 billion.
| Market Cap | 317.16B |
| Enterprise Value | 345.12B |
Important Dates
The next confirmed earnings date is Thursday, April 25, 2024, before market open.
| Earnings Date | Apr 25, 2024 |
| Ex-Dividend Date | Mar 14, 2024 |
Share Statistics
Merck & Co. has 2.53 billion shares outstanding. The number of shares has increased by 0.20% in one year.
| Shares Outstanding | 2.53B |
| Shares Change (YoY) | +0.20% |
| Shares Change (QoQ) | -0.20% |
| Owned by Insiders (%) | 0.05% |
| Owned by Institutions (%) | 78.56% |
| Float | 2.53B |
Valuation Ratios
The trailing PE ratio is 894.50 and the forward PE ratio is 14.47. Merck & Co.'s PEG ratio is 0.10.
| PE Ratio | 894.50 |
| Forward PE | 14.47 |
| PS Ratio | 5.28 |
| Forward PS | 4.93 |
| PB Ratio | 8.44 |
| P/FCF Ratio | 34.69 |
| PEG Ratio | 0.10 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 50.05, with an EV/FCF ratio of 37.75.
| EV / Earnings | 945.55 |
| EV / Sales | 5.74 |
| EV / EBITDA | 50.05 |
| EV / EBIT | 114.17 |
| EV / FCF | 37.75 |
Financial Position
The company has a current ratio of 1.25, with a Debt / Equity ratio of 0.93.
| Current Ratio | 1.25 |
| Quick Ratio | 0.68 |
| Debt / Equity | 0.93 |
| Debt / EBITDA | 5.08 |
| Debt / FCF | 3.83 |
| Interest Coverage | 2.64 |
Financial Efficiency
Return on equity (ROE) is 0.90% and return on invested capital (ROIC) is 0.63%.
| Return on Equity (ROE) | 0.90% |
| Return on Assets (ROA) | 0.30% |
| Return on Capital (ROIC) | 0.63% |
| Revenue Per Employee | $834,931 |
| Profits Per Employee | $5,069 |
| Employee Count | 72,000 |
| Asset Turnover | 0.57 |
| Inventory Turnover | 2.63 |
Taxes
In the past 12 months, Merck & Co. has paid $1.51 billion in taxes.
| Income Tax | 1.51B |
| Effective Tax Rate | 80.55% |
Stock Price Statistics
The stock price has increased by +9.06% in the last 52 weeks. The beta is 0.40, so Merck & Co.'s price volatility has been lower than the market average.
| Beta (1Y) | 0.40 |
| 52-Week Price Change | +9.06% |
| 50-Day Moving Average | 126.05 |
| 200-Day Moving Average | 112.57 |
| Relative Strength Index (RSI) | 45.78 |
| Average Volume (30 Days) | 8,337,719 |
Short Selling Information
The latest short interest is 19.59 million, so 0.77% of the outstanding shares have been sold short.
| Short Interest | 19.59M |
| Short Previous Month | 16.60M |
| Short % of Shares Out | 0.77% |
| Short % of Float | 0.78% |
| Short Ratio (days to cover) | 1.77 |
Income Statement
In the last 12 months, Merck & Co. had revenue of $60.12 billion and earned $365.00 million in profits. Earnings per share was $0.14.
| Revenue | 60.12B |
| Gross Profit | 43.99B |
| Operating Income | 2.36B |
| Pretax Income | 1.88B |
| Net Income | 365.00M |
| EBITDA | 6.90B |
| EBIT | 3.02B |
| Earnings Per Share (EPS) | $0.14 |
Balance Sheet
The company has $7.09 billion in cash and $35.06 billion in debt, giving a net cash position of -$27.96 billion or -$11.04 per share.
| Cash & Cash Equivalents | 7.09B |
| Total Debt | 35.06B |
| Net Cash | -27.96B |
| Net Cash Per Share | -$11.04 |
| Equity / Book Value | 37.58B |
| Book Value Per Share | 14.84 |
| Working Capital | 6.47B |
Cash Flow
In the last 12 months, operating cash flow was $13.01 billion and capital expenditures -$3.86 billion, giving a free cash flow of $9.14 billion.
| Operating Cash Flow | 13.01B |
| Capital Expenditures | -3.86B |
| Free Cash Flow | 9.14B |
| FCF Per Share | $3.60 |
Margins
Gross margin is 73.17%, with operating and profit margins of 3.92% and 0.61%.
| Gross Margin | 73.17% |
| Operating Margin | 3.92% |
| Pretax Margin | 3.12% |
| Profit Margin | 0.61% |
| EBITDA Margin | 11.47% |
| EBIT Margin | 5.03% |
| FCF Margin | 15.21% |
Dividends & Yields
This stock pays an annual dividend of $3.08, which amounts to a dividend yield of 2.46%.
| Dividend Per Share | $3.08 |
| Dividend Yield | 2.46% |
| Dividend Growth (YoY) | 5.63% |
| Years of Dividend Growth | 14 |
| Payout Ratio | 2,200.00% |
| Buyback Yield | -0.20% |
| Shareholder Yield | 2.26% |
| Earnings Yield | 0.12% |
| FCF Yield | 2.88% |
Analyst Forecast
The average price target for Merck & Co. is $131.08, which is 4.67% higher than the current price. The consensus rating is "Buy".
| Price Target | $131.08 |
| Price Target Difference | 4.67% |
| Analyst Consensus | Buy |
| Analyst Count | 13 |
| Revenue Growth Forecast (5Y) | 4.62% |
| EPS Growth Forecast (5Y) | 142.20% |
Stock Splits
The last stock split was on June 3, 2021. It was a forward split with a ratio of 1048:1000.
| Last Split Date | Jun 3, 2021 |
| Split Type | Forward |
| Split Ratio | 1048:1000 |
Scores
Merck & Co. has an Altman Z-Score of 4.19 and a Piotroski F-Score of 6.
| Altman Z-Score | 4.19 |
| Piotroski F-Score | 6 |